Small therapeutic molecules for the treatment of inflammatory bowel disease
- 1 May 2002
- Vol. 50 (Supplement) , iii47-iii53
- https://doi.org/10.1136/gut.50.suppl_3.iii47
Abstract
New therapies for inflammatory bowel disease are needed, because standard therapies fail to induce remission in about 30% of patients, and because of the relative inefficacy of current maintenance therapies. This review summarises the current status of the development of small therapeutic molecules for inflammatory bowel disease.Keywords
This publication has 99 references indexed in Scilit:
- p38MAP Kinase Is a Negative Regulator for ERK1/2-Mediated Growth of AIDS-Associated Kaposi's Sarcoma CellsBiochemical and Biophysical Research Communications, 1999
- Aminoguanidine Has Both an Anti-Inflammatory Effect on Experimental Colitis and a Proliferative Effect on Colonic Mucosal CellsScandinavian Journal of Gastroenterology, 1999
- Activation of nuclear factor kappa B in inflammatory bowel diseaseGut, 1998
- NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune ResponsesAnnual Review of Immunology, 1998
- Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis.Gut, 1996
- Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity.Gut, 1995
- A MAP Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian CellsScience, 1994
- Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in ratsInflammation Research, 1993
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Pyoderma gangrenosum associated with Behçet's disease: Treatment with thalidomideJournal of the American Academy of Dermatology, 1990